Hormonal
Selective beta-3 adrenergic receptor (beta3AR) agonists prevent or reverse obesity and stimulate thermogenesis in animal models by inducing brown adipocytes in white fat and increasing energy expenditure, independent of food intake.
This research highlights beta-3 adrenergic receptors as a key target for treating obesity by increasing energy expenditure (thermogenesis) rather than suppressing appetite. While effective in animals, human application is complicated by lower receptor density. Future treatments may require highly selective drugs to be effective in humans.
selective beta3AR agonists are able to prevent or reverse obesity and loss of beta3AR expression and to stimulate thermogenesis.
Why this rating
Strong evidence in multiple animal models (mice, rats, primates), but human efficacy is debated due to receptor differences.
Source
The -Adrenergic Receptors and the Control of Adipose Tissue Metabolism and Thermogenesis
Sheila Collins · Recent Progress in Hormone Research · 2001
DOI 10.1210/rp.56.1.309
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →